`Brittain et al.
`
`(10) Patent No.:
`(45) Date of Patent:
`
`US 8,791,270 B2
`Jul. 29, 2014
`
`US00879l270B2
`
`(54) BENDAMUSTINE PHARMACEUTICAL
`COMPOSITIONS
`
`(71) Applicant: Cephalon, Inc., Frazer, PA (US)
`
`(72)
`
`Inventors: Jason Edward Brittain, El Cajon, CA
`(US); Joe Craig Franklin, Tulsa, OK
`(US)
`
`(73) Assignee: Cephalon, Inc., Frazer, PA (US)
`
`( * ) Notice:
`
`Subject to any disclaimer, the term of this
`patent is extended or adjusted under 35
`U.S.C. 154(b) by 0 days.
`
`(21) Appl.No.: 13/969,724
`
`(22)
`
`Filed:
`
`Aug. 19, 2013
`
`(65)
`
`Prior Publication Data
`
`US 2013/0338205 A1
`
`Dec. 19, 2013
`
`Related U.S. Application Data
`
`(63) Continuation of application No. 13/719,409, filed on
`Dec. 19, 2012, which is a continuation of application
`No. 13/654,898, filed on Oct. 18, 2012, now Pat. No.
`8,461,350, which is a continuation of application No.
`11/330,868, filed on Jan. 12, 2006, now Pat. No.
`8,436,190.
`
`(60) Provisional application No. 60/644,354, filed on Jan.
`14, 2005.
`
`(51)
`
`(2006.01)
`(2006.01)
`(2006.01)
`(2006.01)
`(2006.01)
`
`Int. Cl.
`C07D 235/04
`A61K 47/10
`A61K 31/4184
`A61K 9/19
`A61K 9/00
`(52) U.S. Cl.
`CPC .A61K 9/19 (2013.01); A61K 47/10 (2013.01);
`A61K31/4184 (2013.01); A61K 9/0019
`(2013.01)
`USPC ........................................ .. 548/304.7; 34/284
`(58) Field of Classification Search
`USPC .......................................................... .. 34/284
`See application file for complete search history.
`
`(56)
`
`References Cited
`U.S. PATENT DOCUMENTS
`
`3,590,028 A
`4,012,448 A
`4,537,883 A
`4,659,699 A
`4,670,262 A
`4,959,215 A
`5,036,060 A
`5,066,647 A
`5,130,305 A
`5,183,746 A
`5,192,743 A
`5,204,335 A
`5,227,373 A
`5,227,374 A
`
`6/1971 Report et al.
`3/1977 Smith et al.
`8/1985 Alexander et al.
`4/1987 Francis
`6/1987 Battelli et al.
`9/1990 Sauerbier et al.
`7/1991 Alam et al.
`11/1991 Palepu et al.
`7/1992 Palepu et al.
`2/1993 Shaked et al.
`3/1993 Hsu et al.
`4/1993 Sauerbier et al.
`7/1993 Alexander et al.
`7/1993 Alexander et al.
`
`5,268,368 A
`5,413,995 A
`5,418,223 A
`5,750,131 A
`5,770,230 A
`5,776,456 A
`5,955,504 A
`5,972,912 A
`6,034,256 A
`6,077,850 A
`6,090,365 A
`6,271,253 B1
`6,380,210 B1
`6,492,390 B2
`6,545,034 B1
`6,569,402 B1
`6,573,292 B1
`6,613,927 B1
`6,780,324 B2
`8,420,130 B1
`8,436,190 B2
`2002/0031527 A1
`2002/0102215 A1
`2003/0232874 A1
`2004/0053972 A1
`2004/0058956 A1
`2004/0072889 A1
`2004/0096436 A1
`2004/0152672 A1
`2004/0247600 A1
`2005/0020615 A1
`2005/0060028 A1
`2005/0176678 A1
`2006/0051412 A1
`2006/0128777 A1
`
`12/1993 Palepu
`5/1995 Alexander et al.
`5/1995 Palepu et al.
`5/1998 Wichert et al.
`6/1998 Teagarden et al.
`7/1998 Anderson et al.
`9/1999 Wechter et al.
`10/1999 Marek et al.
`3/2000 Carter et al.
`6/2000 Carter et al.
`7/2000 Kaminski et al.
`8/2001 Carter et al.
`4/2002 DeSimone et al.
`12/2002 Carter et al.
`4/2003 Carson et al.
`5/2003 Cheesman et al.
`6/2003 Nardella
`9/2003 Kwok
`8/2004 Le Garrec et al.
`4/2013 Nuijen et al.
`5/2013 Brittain et al.
`3/2002 Wu et al.
`8/2002 Klaveness et al.
`12/2003 Nardella
`3/2004 Nara
`3/2004 Akiyama et al.
`4/2004 Masferrer
`5/2004 Carson et al.
`8/2004 Carson et al.
`12/2004 Leoni
`1/2005 Rubino
`3/2005 Horres et al.
`8/2005 Horres et al.
`3/2006 Petereit et al.
`6/2006 Bendall et al.
`
`(Continued)
`
`DE
`DE
`DE
`DE
`DE
`DE
`DE
`DE
`DE
`EP
`
`FOREIGN PATENT DOCUMENTS
`
`34727 A1
`80967 C
`159289 Al
`159877 Al
`3907079
`293808 A5
`10016077 A1
`10306724 Al
`10304403 Al
`334083 Al
`
`12/1964
`6/1970
`3/1983
`4/1983
`9/1989
`9/1991
`12/2001
`9/2003
`8/2004
`9/1989
`
`(Continued)
`
`OTHER PUBLICATIONS
`
`Avis et al., “Pharmaceutical Dosage Forms: Parenteral Medications
`vol. 1” Marcel Dekker Inc, 1992, pp. 217-227.
`
`(Continued)
`
`Primary Examiner — Ali Soroush
`(74) Attorney, Agent, or Firm — Baker & Hostetler LLP
`
`(57)
`
`ABSTRACT
`
`The present invention provides pharmaceutical formulations
`of lyophilized bendamustine suitable for pharmaceutical use.
`The present invention further provides methods of producing
`lyophilized bendamustine. The pharmaceutical formulations
`can be used for any disease that is sensitive to treatment with
`bendamustine, such as neoplastic diseases.
`
`23 Claims, 6 Drawing Sheets
`
`FRESENIUS KABI 1001-OOO1
`
`
`
`US 8,791,270 B2
`Page 2
`
`(56)
`
`References Cited
`U.S. PATENT DOCUMENTS
`
`2009/0264488 A1
`2011/0190363 A1
`2012/0071532 A1
`2013/0041003 A1
`2013/0123316 A1
`
`10/2009 Cooper et al.
`8/2011 Drager et al.
`3/2012 Cooper et al.
`2/2013 Brittain et al.
`5/2013 Brittain
`
`FOREIGN PATENT DOCUMENTS
`
`0656211 A1
`EP
`0780386 A1
`EP
`1354952 A1
`EP
`1444989 A1
`EP
`WO 96/28148 A2
`W0
`W0 97/08174 A1
`W0
`W0 03/066027 A1
`W0
`W0 03/077882 A2
`W0
`W0 03/081238 A2
`W0
`W0 03/086470 A2
`W0
`W0 03/094990 A1
`W0
`W0 W0 2004/041118 A2
`W0 W0 2006/076620 A2
`W0 W0 2009/120386 A2
`
`6/1995
`6/1997
`10/2003
`8/2004
`9/1996
`3/1997
`8/2003
`9/2003
`10/2003
`10/2003
`11/2003
`5/2004
`7/2006
`10/2009
`
`OTHER PUBLICATIONS
`
`fur
`
`from Rote Liste 2003, Arzneimittelverzeichnis
`Excerpt
`Deutschland, 2 pages.
`Flamberg, et al., “Low Temperature Vacuum Drying of Sterile
`Parenterals from Ethanol” Bulletin of the Parenteral Drug Associa-
`tion, Sep.-Oct. 1970, 24(5), 209-217.
`IMET 3393”,
`Furst et al.,
`“The hydrolytic degradation of
`Pharmazeutische Zentralhalle Fur Deutschland 1969, 108(9), 608-
`614.
`Gandhi et al., “Bendamustine in B Cell Malignancies: The New,
`46-year old kid on the Block” Clinical Cancer Research, Dec. 2009,
`15(24), 7456-7461.
`Jennings,Thomas A., “Extracts from Lyophilization. Introduction
`and Basic Principles”. 2002, by CRC Press LLC, Boca Raton,
`Florida, 33431.
`Jonkmarm-de Vries et al., “Pharmaceutical Development of (Inves-
`tigational) Anticancer Agents for Parenteral Use-A Review Drug
`Development and Industrial Pharmacy”, 1996, 22(6), 475-494.
`Kasraian et al., “The Effect of Tertiary Butyl Alcohol on the Resis-
`tance of the Dry Product Layer During Primary Drying”, 1995,
`Pharm. Res, 12(4), 491-495, hier: Zusammenfassung.
`Kasraian et al., “Thermal Analysis of the Tertiary Butyl Alcohol-
`Water System and its Implications on Freeze-Drying”, 1995, Pharm.
`Res, 12(4), 484-90, hier: Zusammenfassung.
`Kibbe, Arthur, H., Handbook Pharmaceutical Excipients, 3rd Edi-
`tion, 2000, Mannitol, American Pharmaceutical Association and
`Pharmaceutical Press.
`Kim, et al., “The Physical State of Marmitol after Freeze-Drying:
`Effects of Marmitol Concentration, Freezing Rate, and a Noncrystal-
`lizing Cosolute” Journal of Pharmaceutical Sciences, 87(8), Aug.
`1998, 931-935.
`a Parenteral
`“Pharmaceutical Development of
`Nuijen, B.,
`Lyophilized Formulation of the Novel Antitumor Agent Aplidine”,
`PDA Journal of Pharmaceutical Science and Technology, May/Jun.
`2000, 54(3), 193-208.
`Oesterle, et al., “The Influence ofTertiary Butyl Alcohol andVolatile
`Salts on the Sublimation of Ice From Frozen Sucrose Solutions:
`Implications for Freeze- Drying” Pharmaceutical Development and
`Technology, 1998, 3(2), 175-183.
`Rey et al., "Freeze-Drying/Lyophilization of Pharmaceutical and
`Biological Products”, Second Edition, revised and expanded, New
`York, Taylor and Francis Group, 2004, Seiten 239-243.
`Rowe et al., “Handbook of Pharmaceutical Excipients” Fourth Edi-
`tion, The Royal Pharmaceutical Society of Great Britain, 2003, pp.
`373-377.
`
`Rowe, et al, Handbook of Pharmaceutical Excipients, Sixth Edition,
`Pharmaceutical Press and the American Pharmacists Association,
`Royal Pharmaceutical Society of Great Britain, 2009,16 pages.
`Seager et al., Structure of Products Prepared by Freeze-Drying Solu-
`tions Containing Organic Solvents, PDA Journal of Pharmaceutical
`Science and Technology, Jul.-Aug. 1985, 39(4), 161-179, hier.
`Zusammenfassung.
`Tang, X. and Pikal, M. J., “Design of Freeze-Drying Processes for
`Pharmaceuticals: Practical Advice” Pharmaceutical Research, 21(2)
`, Feb. 2004, 191-200.
`Telang, C. and Suryanarayanan, R., “Crystallization of Cephalothin
`Sodium During Lyophilization from Tert-Butyl Alcohol-Water
`Cosolvent System” Pharmaceutical Research, Jan. 2005, 22(1),153-
`160.
`Van Drooge et al., “Incorporation of Lipophilic Drugs in Sugar
`Glasses by Lyophilixation using a Mixture of Water and Tertiary
`Butyl Alcohol as Solven ” Journal of Pharmaceitical Sciences, Mar.
`2004, 93(3), 713-725.
`J., Handbook of Pharmaceutical
`Wade,A. and Weller, Paul
`Excipients, Second Edition, American Pharmaceutical Association,
`Washington and The Pharmaceutical Press, London, 1994, pp. 294-
`298.
`Wittaya-Areekul, Sakchai et al., Freeze-Drying of tert-Butanol/Wa-
`ter Cosolvent Systems: A Case Report on Formation of a Friable
`Freeze-Dried Powder of Tobramycin Sulfate Journal of Pharmaceu-
`tical Sciences, 91(4), Apr. 2002,1147-1155.
`Aivado et al., “Bendamustine in the Treatment of Chronic
`Lymphocytic Leukemia: Results and Future Perspectives”, Seminars
`in Oncology, Aug. 2002, 29(4), 19-22, Suppl. 13.
`Barman Balfour et al., “Bendamustine”, Drugs, 2001, 61(5), 631-
`638, Auckland, New Zealand.
`Berge et al., “Pharmaceutical Salts”, Journal of pharmaceutical sci-
`ences, Jan. 1977, 66(1), 1-19.
`Bremer, Karl, “High Rates of Long-Lasting Remissions After 5-Day
`Bendamustine Chemotherapy Cycles in Pre-Treated Low-Grade
`Non-Hodgkin’s-Lymphomas”, Journal of Cancer Research and
`Clinical Oncology, Nov. 2002, 128(11), 603-609.
`Byrn et al., “Pharmaceutical Solids: A Strategic Approach to Regu-
`latory Consideration”, Pharmaceutical Research, Jul. 1995, 12(7),
`945-954.
`Chow et al., “Anti-Cd20 Antibody (Idec -C2b8, Rituximab) Enhances
`Efficacy of Cytotoxic Drugs on Neoplastic Lymphocytes In Vitro:
`Role ofCytokines Complement, and Caspases”, Haematologica, Jan.
`2002, 87(1), 33-43.
`Chow et al., “In AML Cell Lines Ara-C Combined with Purine
`Analogues is Able to Exert Synergistic as Well as Antagonistic
`Effects on Proliferation, Apoptosis and Disruption of Mitochondrial
`Membrane Potential”, Leukemia & Lymphoma, 2003, 44(1), 165-
`173.
`Chow et al., “Synergistic Effects of Chemotherapeutic Drugs in
`Lymphoma Cells Are Associated With Down-Regulation of Inhibitor
`of Apoptosis Proteins (Laps), Prostate- Apoptosis-Response-Gene
`4(Par-4), Death-Associated Protein (Dazz) and With Enforced
`Caspase Activation”, Biochemical Pharmacology, Jan. 2003, 66(5),
`71 1-724.
`Department of Health and Human Services, Food and Drug Admin-
`istration, “International Conference on Harmonisation; Guidance on
`Impurities: Residual Solvents,” Federal Register, Dec. 24, 1997,
`62(247), 67377-67388.
`Diehl et al., “Bendamustine in the Treatment of Hematologic Malig-
`nancies”, Semin. Oneal., Aug. 2002, 29(4), 1-3, Suppl. 13, Saundes,
`Philadelphia, PA.
`Fichtner et al., “Antineoplastic Activity and Toxicity of Some
`Alkylating Cytostatics
`(Cyclophosphamide, Ccnu, Cytostasan)
`Encapsulated in Liposomes in Different Murine Tumor Models”,
`Journal of Microencapsulation, Jan. 1986, 3(2), 77-87.
`Gandhi, Varsha, “Metabolism and Mechanisms of Action of
`Bendamustine: Rationales for Combination Therapies”, Seminars in
`Oncology, Aug. 2002, 29(4), 4-11, Suppl. 13.
`Goodman et al., The Pharmacological Basis of Therapeutics, 1985,
`7th edition, Macmillan publishing company, New York.
`
`FRESENIUS KABI 1001-0002
`
`
`
`US 8,791,270 B2
`Page 3
`
`(56)
`
`References Cited
`OTHER PUBLICATIONS
`
`Heider et al., “Efficacy and Toxicity of Bendamustine in Patients
`With Relapsed Low-Grade Non-Hodgkin ’s Lymphomas”, Anti-
`Cancer Drugs, Oct. 2001, 12(9), 725-729.
`Kath et al., “Bendamustine Monotherapy in Advanced and Refrac-
`tory Chronic Lymphocytic Leukemia”, Journal of Cancer Research
`and Clinical Oncology, Jan. 2001, 127(1), 48-54.
`Koenigsman et al., “Fiudarabine and Bendamustine in Refractory
`and Relapsed Indolent Lymphoma a Multicenter Phase 1 1 11 Trial of
`the East German Society of Hematology and Oncology (OSHO)”,
`Leukemia & Lymphoma, Sep. 2004, 45(9), 1821-1827.
`Kollmarmsberger et al., “Phase Ii Study of Bendamustine in Patients
`With Relapsed or Cisplatin-Refractory Germ Cell Cance”r, Anti-
`Cancer Drugs, Aug. 2000, 11(17), 535-539.
`Konstantinov et al., Cytotoxic Efficacy of Bendamustine in Human
`Leukemia and Breast Cancer Cell Lines, Journal of Cancer Research
`and Clinical Oncology, May 2002, 128(5), 271-278.
`Leoni et al., “Sdx- 105 (Trenda), Active in Non-Hodgkins Lymphoma
`Cells, Induces the Mitotic Catastrophe Death Pathway”, Blood,
`104(11), 2004, Abs 4593, p. 232b.
`in
`Benamustinhydrochlorid
`Vlaas,
`“Stabilitat
`von
`Infusionslosungen”, Pharmazie, 1994, 49(10), 775-777 (Translation
`Included).
`VIcKim et al., “Dimethyl Sulfoxide USP, PhEur in Approved Phar-
`maceutical Products and Medical Devices,” Pharmaceutical Technol-
`ogy, May 2, 2008, 1-7.
`\/Iottu et al., “Organic Solvents for Pharmaceutical Parenterals and
`Embolic Liquids: A Review ofToxicity Data,” PDA J. Pharma. Sci. &
`Tech. 54(6) Nov.- Dec. 2000, 456-469.
`\Ii et al., “Use of Pure T-Butanol as a Solvent for Freeze-Drying: A
`Case Study”, International Journal of Pharmaceutics, Sep. 2001,
`226(1-2), 39-46.
`\Iiemeyer et al., “SDX-105 (bendamustine) is a Clinically Active
`Chemotherapeutic Agent With a Distinct Mechanism of Action”,
`Proc Annu Meet Am Assoc Cancer Res, Mar. 2004, 45, 1st ed., 2
`pages.
`\Iowak et al., “Upon Drug-Induced Apoptosis in Lymphoma Cells X-
`linked Inhibitor of Apoptosis (XIAP) Translocates from the Cytosol
`to the Nucleus”, Leukemia & Lymphoma, Jul. 2004, 45(7), 1429-
`1436.
`Ozegowski et al., “IMET 3393, garnrna-(1-methyl-5-bis-( -chlor-
`athyl)-amino-benzimidazolyl(2)-buttersaure-hydrochlorid,
`ein
`neues Zytostatikum aus der Reihe der Benzimidazoi-Loste”, Zbl
`Pharm., 1971;110, Heft 10, 1013-1019 (Translation Included).
`Remington: Pharmaceutical Sciences, 1990, Mack Publishing com-
`pany, Easton, Pennsylvania.
`Ribomustin: Bendamustine Product Monograph, Jan. 2002, 3-58,
`Ribosepharm GMBH, Munchen, Germany.
`Ribomustin: Bendamustine Product Monograph, Mar. 2005, 3-73,
`Ribosepharm MBH, Munchen, Germany.
`Rummel et al., “In Vitro Studies With Bendaustine: Enhanced Activ-
`ity in Combination With Rituxima ”, Seminars in Oncology, Aug.
`2002, 29(4), 12-14, Suppl. 13.
`Scasnar et al., “Stability Studies of 14c-Cytostasan Solutions and Its
`Extraction Using Dicarbolide of Cobalt,” Die Pharn1azie, Mar. 1988,
`43(3), 176-179.
`Schmidt-Hieber et al., “A Phase II Study of Bendamustine Chemo-
`therapy As Second-Line Treatment in Metastatic Uveal Melanoma”,
`Melanoma Research, Dec. 2004, 14(6), 439-442.
`Schoffski et al., “Repeated Administration of Short Infusions of
`Bendamustine: A Phase I Study in Patients With Advanced Progres-
`sive Solid Tumors”, Journal of Cancer Research and Clinical Oncol-
`ogy, Jan. 2000, 126(1), 41-47.
`
`Schrijvers et al., “Phase I Studies with Bendamustine: An update”,
`Seminars in Oncology, Aug. 2002, 29(4), 15-18, Suppl. 13.
`Schwanen et al., “In Vitro Evaluation of Bendamustine Induced
`Apoptosis in B-Chronic Lymphocytic Leukemia”, Leukemia, Oct.
`2002, 16(10), 2096-2105.
`Strumberg et al., “Bendamustine Hydrochloride Activity Against
`Doxorubicin-Resistant Human Breast Carcinoma C ell Lines”, Anti-
`Cancer Drugs, Jun. 1996, 7(4), 415-421.
`Weide et al., “Bendamustine Mitoxantrone and Rituximab (BMR): A
`New Effective Regimen for Refractory or Relapsed Indolent
`Lymphomas”, Leukemia & Lymphoma, Feb. 2002, 43(2), 327-331.
`Weide et al., "Bendamustine/Mitoxantrone/Rituximab (BMR): A
`Very Effective, Well Tolerated Outpatient Chemoimmunotherapy for
`Relapsed and Refractory CD20-positive Indolent Malignancies.
`Final Results of a Pilot Study”, Leukemia & Lymphoma, Dec. 2004,
`45(12), 2445-2449.
`Weidmann et al., “Bendamustine is Effective in Relapsed or Refrac-
`tory Aggressive non-Hodgkin’s Lymphoma”, Annals of Oncology,
`Aug. 2002, 13(8), 1285-1289.
`Werner et al., “Hydrolyseprodukte des Cancero staticums Cyto stasan
`(Bendamustin)”, Pharmazie, Apr. 1987, 42, 272-273.
`Zulkowski, et al., “Regression of Brain Metastases From Breast
`Carcinoma After Chemotherapy With Bendamustine”, Journal of
`Cancer Research and Clinical Oncology, Feb. 2002, 128(2), 111-113.
`Chow et al., “In Vitro Induction of Apoptosis of Neoplastic Cells in
`Low-Grade Non-Hodkin ’s Lymphomas by Combinations of Estab-
`lished Cytotoxic Drugs With Bendamustine”, Haematologica, May
`2001, 86(5), 485-493.
`EC Safety Data Sheet: Ribomustin® in http://www.docstoc.com/
`doc s/2232323 1/EC-Safety-Data-Sheet-Bendamustin
`(published:
`Jul. 3, 1998; updated Mar. 1, 2007), 8 pages.
`Gust et al., “Investigations on the Stability of Bendamustin, a
`Cytostatic Agent of the Nitrogen Mustard Type, I. Synthesis, Isola-
`tion, and Characterization of Reference Substances”, Monatshefte
`fur Chemie, 1997, 128(3), 291-299.
`Kanekal et al., “SDX-105(TREANDA) Enhances the Tumor Growth
`Inhibitory Effect of Rituximab in Daudi Lymphoma Xenografts”,
`2004, Blood, ASH Annual Meeting Abstracts, 104, Abstract 4580.
`Koster et al., “Carboplatin in Combination With Bendamustine in
`Previously Untreated Patients With Extensive-Stage Small Lung
`Cancer (SCLC)”, Clinical Drug Investigation, 2004, 24(10), 611-
`618.
`Ponisch et al., “Bendamustine in the Treatment of Multiple
`Myeloma: Results and Future Perspectives”, Seminars in Oncology,
`Aug. 2002, 29(4), 23-26, Suppl. 13.
`Preiss et al., “Pharmacokinetics of Bendamustin (Cytostasan) in
`Patients”, Pharmazie, Mar. 1985, 40(11), 782-784.
`Rummel et al., “Bendamustine in the Treatment of Non-Hodgkin ’s
`Lymphoma: Results and Future Perspectives”, Seminars in Oncol-
`ogy, Aug. 2002, 29(4), 27-32, Suppl. 13.
`Rxlist, The Internet Drug Index, Treanda®, 2013, pp. 1-2, http://
`www.rxlist.com/script/main/rxlist.asp?articleke}P88624&pf:3
`&page:1.
`Scasnar et al., “Radiochemical Assay of Stability of MC-Cytostasan
`Solutions During Preparation and Storage”, Journal of Radioanalyti-
`cal and Nuclear Chemistry, 1998, 121(2), 489-497.
`Teagarden et al., “Practical Aspects of Lyophilization Using Non-
`Aqueous Co-Solvent Systems,” European Journal of Pharmaceutical
`Sciences, Mar. 2002, 15(2), 115-133.
`Wittaya-Areekul et al., “Freeze-Drying of Tert-Butyl Alcohol/Water
`Cosolvent Systems: Effects of Formulation and Process Variables on
`Residual Solvents,” Journal of Pharmaceutical Sciences, Apr. 1998,
`87(4), 491-495.
`
`FRESENIUS KABI 1001-0003
`
`
`
`U.S. Patent
`
`Jul. 29, 2014
`
`Sheet 1 of6
`
`US 8,791,270 B2
`
`asE:§~IT
`
`«E.E:Nomi!
`
`xxxx
`
`3
`
`8;mnsuwummfioe
`
`(1111/3111) uogqenuaouog
`
`FRESENIUS KABI 1001-OOO4
`
`
`
`
`
`U.S. Patent
`
`Jul. 29, 2014
`
`Sheet 2 of6
`
`US 8,791,270 B2
`
`E]10%(V/v)Z20%(v/v)S30%(v/v)
`
`
`
`'°
`
`
`Ziig
`s\\\\\\\\\\\\\\\V
`9;;
`gflii
`35
`
`EEH
`
`E1
`§
`
`m.
`
`
`
`
`,3;-,-;;,g.
`
`ESEEEEE
`5:
`
`giifs‘
`ggggg
`
`
`
`
`
`
`
`g}; 5
`:::
`:
`5%
`
`
`(WV :4) mind
`
`FRESENIUS KABI 1001-OOO5
`
`
`
`U.S. Patent
`
`Jul. 29, 2014
`
`Sheet 3 of6
`
`US 8,791,270 B2
`
`
`
`Sufism_onmmo.E
`
`ms@
`
`o
`
`...t£.Sufism£fioammoumBnmfimI
`
`
`
`
`
`33NS§33umI3:5.D
`
`E:wasM93N8VA
`
`///é
`\\V‘
`
`IIIIIIII
`'/////////A
`\\\\\\\\\\\\\\\\\\N
`
`i
`
`\\\\\\\\\\\\\\\\\.‘\‘
`
`u
`'
`
`I
`Illllll
`%’///////A
`k\\\\\\\\\\\\\\\‘
`
`i 7
`
`///’
`
`(WV 24) HH
`
`
`
`flnozomlou.H3mB\~onoo_<
`
`
`
`m=oEw>EPmemEhsmmafi§umfimnosmasfiam
`
`FRESENIUS KABI 1001-0006
`
`
`
`
`U.S. Patent
`
`Jul. 29, 2014
`
`Sheet 4 of6
`
`US 8,791,270 B2
`
`>I>gX‘\
`>‘I>:<*,J:,
`x./sagxx
`x s\°’5oo
`©|.Dv-ICVOD
`
`EIIIIIII
`
`I
`I
`I
`I
`
`I
`I
`I
`;
`
`I
`
`'
`
`I
`
`'
`
`IIIIIIIIIIIIIIIIIIIIIIIIIIIIII
`
`‘L 3
`3 3
`3 .2
`
`I
`.
`;
`
`IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII
`
`\n~
`Ks,
`N
`E»
`
`§
`--« I
`I
`I
`I
`E
`I IIIIIIIIIIIIIIIIIIIIIIIIIIIIII 3.
`I
`.
`,3
`'////////)///////////4:
`:1
`I
`I
`-
`.~,\\\\\\\\\\\\\\\\\\\\\\\\\
`,3
`I
`.
`§.>
`I I m
`33
`I
`I
`I
`I
`3 Ԥ
`rs
`3 g I
`I
`I
`7 '
`5
`3 8 ~
`I
`O Q.
`'
`I
`VJ
`.\
`3* 2
`o
`»
`E0I A
`3 53
`I
`I
`I
`32%:
`I ' '5'
`3;;
`I m\\\\\\\\\\\\\\\\\\\\\\\\‘\\\\\\\\\\\\\\\\\\\: §
`§ 8' 3
`Q 2 I
`I
`I
`|
`Q‘.
`IIIIIIIIIIIIIIIIIIIIIIIIIIIIII
`-9
`I
`I
`I
`'
`'///////////////////////A '§
`*3
`I
`I
`I
`3
`g
`I
`'
`'
`‘Z I H
`E
`I
`'
`I
`'
`b
`.
`I
`.
`' IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII 7.
`I
`I
`I
`gs
`.
`g
`.\\\\\\\\\\\\\\\\\\\\\\\\\\V 5:
`I
`<1)
`I 2
`I j
`ouoonoou: c:
`°'-?
`C‘!
`‘‘§‘'I‘'I
`5?
`°.
`:3 coo O
`o
`c
`
`(vaxvz) .I9U.I1([
`
`FRESENIUS KABI 1001-OOO7
`
`
`
`U.S. Patent
`
`Jul. 29, 2014
`
`Sheet 5 of6
`
`US 8,791,270 B2
`
`8:.mean8%23Sum£392men.
`
`
`
`
`
`EacfibHE==om>gmmnowuoouoamefinuoumm.._o=uo.£muosuonmfigonconm
`
`
`
`
`
`laxxx
`
`FRESENIUS KABI 1001-OOO8
`
`
`
`SU
`
`M
`
`00
`
`1,97,
`
`2B
`
`tm888.mm_88.8t3pmW8.8
`.m83
`
`aomd
`
`m8383:m8.888.8888.88.88.8.8.88.8888.888.28.288.:
`
`
`
`8.8.88.288.88.88....88.8m88.8
`
`nuUummmomodM6M._m_.88888.88.8.m
`mllw.oi.8
`
`Eod
`
`888.8
`
`
`
`
`
`s83:52U8.888.888.8888.8888.888.888.28.288.:88.888.388.888.888.888.8
`
`m8$88
`
`
`FRESENIUS KABI 1001-0009
`
`
`
`US 8,791,270 B2
`
`1
`BENDAMUSTINE PHARMACEUTICAL
`COMPOSITIONS
`
`CROSS REFERENCE TO RELATED
`APPLICATIONS
`
`This application is a continuation of U.S. application Ser.
`No. 13/719,409, filed Dec. 19, 2012, which is a continuation
`ofU.S. application Ser. No. 13/654,898, filed Oct. 18, 2012,
`now U.S. Pat. No. 8,461,350, which is a continuation ofU.S.
`application Ser. No. 11/330,868, filed Jan. 12, 2006, now U.S.
`Pat. No. 8,436,190, which claims the benefit of U.S. Provi-
`sional Application No. 60/644,354, filed Jan. 14, 2005, the
`entireties of which are incorporated herein for all purposes.
`
`FIELD OF THE INVENTION
`
`The present invention pertains to the field of pharmaceuti-
`cal compositions for the treatment of various disease states,
`especially neoplastic diseases and autoimmune diseases. Par-
`ticularly, it relates to pharmaceutical formulations compris-
`ing nitrogen mustards, particularly the nitrogen mustard ben-
`darnustine, e.g., bendamustine HCl.
`
`BACKGROUND OF THE INVENTION
`
`The present invention claims the benefit of and priority to
`U.S. Ser. No. 60/644,354, filed Jan. 14, 2005, entitled, “Ben-
`damustine Pharmaceutical Compositions,” which is incorpo-
`rated herein by reference in its entirety, including figures and
`claims.
`
`The following description includes information that may
`be useful in understanding the present invention. It is not an
`admission that any such information is prior art, or relevant, to
`the presently claimed inventions, or that any publication spe-
`cifically or implicitly referenced is prior art.
`Because oftheir high reactivity in aqueous solutions, nitro-
`gen mustards are difficult to formulate as pharmaceuticals
`and are often supplied for administration in a lyophilized
`form that requires reconstitution, usually in water, by skilled
`hospital personal prior to administration. Once in aqueous
`solution, nitrogen mustards are subject to degradation by
`hydrolysis, thus, the reconstituted product should be admin-
`istered to a patient as soon as possible after its reconstitution.
`Bendamustine,
`(4-{5-[Bis(2-chloroethyl)arnino]-1-me-
`thyl-2-benzimidazolyl}butyric acid, is an atypical structure
`with a benzimidazole ring, whose structure includes an active
`nitrogen mustard (see Formula I, which shows bendamustine
`hydrochloride).
`
`Formula I
`
`2
`
`Bendamustine was initially synthesized in 1963 in the Ger-
`man Democratic Republic (GDR) and was available from
`1971 to 1992 in that location under the name Cytostasan®.
`Since that time, it has been marketed in Germany under the
`tradename Ribomustin®. It has been widely used in Germany
`to treat chronic lymphocytic leukemia, Hodgkin’s disease,
`non-Hodgkin’s lymphoma, multiple myeloma, and breast
`cancer.
`
`Due to its degradation in aqueous solutions (like other
`nitrogen mustards), bendamustine is supplied as a lyophilized
`product. The current lyophilized formulation of bendarnus-
`tine (Ribomustin®) contains bendamustine hydrochloride
`and mannitol in a sterile lyophilized form as a white powder
`for intravenous use following reconstitution. The finished
`lyophilisate is unstable when exposed to light. Therefore, the
`product is stored in brown or amber-colored glass bottles. The
`current lyophilized formulation of bendamustine contains
`degradation products that may occur during manufacturing of
`the drug substance and/or during the lyophilization process to
`make the finished drug product.
`Currently bendamustine is formulated as a lyophilized
`powder for injection with 100 mg of drug per 50 mL vial or 25
`mg of drug per 20 mL vial. The vials are opened and recon-
`stituted as close to the time of patient administration as pos-
`sible. The product is reconstituted with 40 mL (for the 100 mg
`presentation) or 10 mL (for the 25 mg presentation) of Sterile
`Water for Injection. The reconstituted product
`is further
`diluted into 500 mL, q.s., 0.9% Sodium Chloride for Injec-
`tion. The route of administration is by intravenous infusion
`over 30 to 60 minutes.
`
`Following reconstitution with 40 mL Sterile Water for
`Injection, vials of bendamustine are stable for a period of 7
`hours under room temperature storage or for 6 days upon
`storage at 2-8° C. The 500 mL admixture solution must be
`administered to the patient within 7 hours of vial reconstitu-
`tion (assuming room temperature storage of the admixture).
`The reconstitution ofthe present bendamustine lyophilized
`powder is difiicult. Reports from the clinic indicate that
`reconstitution can require at least fifteen minutes and may
`require as long as thirty minutes. Besides being burdensome
`and time-consuming for the healthcare professional respon-
`sible for reconstituting the product, the lengthy exposure of
`bendamustine to water during the reconstitution process
`increases the potential for loss of potency and impurity for-
`mation due to the hydrolysis of the product by water.
`Thus, a need exists for lyophilized formulations of benda-
`mustine that are easier to reconstitute and which have a better
`
`impurity profile than the current lyophilate (lyophilized pow-
`der) formulations of bendamustine.
`German (GDR) Patent No. 34727 discloses a method of
`preparing oo-[5-bis-([3-chloroethyl)-amino-benzimidazolyl-
`(2)]-alkane carboxylic acids substituted in the 1-position.
`German (GDR) Patent No. 80967 discloses an injectable
`preparation of y-[1-methyl-5-bis-([3-chloroethyl)-amino-
`benzimaidazolyl-(2)] -butric acid hydrochloride.
`German (GDR) Patent No. 159877 discloses a method for
`preparing 4-[1-methyl-5 -bis(2-chloroethyl)amino -benzimi-
`dazolyl-2)-butyric acid.
`German (GDR) Patent No. 159289 discloses an injectable
`solution of bendamustine.
`
`Ribomustin® bendamustine Product monograph (updated
`1/2002) http ://www.ribosepharrn. de/pdf/ribomustin_benda-
`
`10
`
`15
`
`20
`
`25
`
`30
`
`35
`
`40
`
`45
`
`50
`
`55
`
`60
`
`65
`
`FRESENIUS KABI 1001-0010
`
`
`
`US 8,791,270 B2
`
`3
`mustin/productmonograph.pdf provides information about
`Ribomustin® including product description.
`Ni et al. report that the nitrosourea SarCNU was more
`stable in pure tertiary butanol than in pure acetic acid, dim-
`ethyl sulfoxide, methylhydroxy, water or in TBA/water mix-
`tures (Ni et al. (2001) Int]. J. Phamaceuzics 226239-46).
`Lyophilized cyclophosharnide is known in the art see e.g.,
`U.S. Pat. Nos. 5,418,223; 5,413,995; 5,268,368; 5,227,374;
`5,130,305; 4,659,699; 4,537,883; and 5,066,647.
`The lyophilized nitrogen mustard Ifosfarnide is disclosed
`in International Publication No. WO 2003/066027; U.S. Pat.
`Nos. 6,613,927; 5,750,131; 5,972,912; 5,227,373; and 5,204,
`335.
`
`Teagarden et al. disclose lyophilized formulations of pros-
`taglandin E-1 made by dissolving PGE-1 in a solution of
`lactose and tertiary butyl alcohol (U.S. Pat. No. 5,770,230).
`
`SUMMARY OF THE INVENTION
`
`The present invention is directed to stable pharmaceutical
`compositions of nitrogen mustards, in particular lyophilized
`bendamustine and its use in treatment of various disease
`
`states, especially neoplastic diseases and autoimmune dis-
`eases.
`
`An embodiment of the invention is a pharmaceutical com-
`position of bendamustine containing not more than about
`0.5% to about 0.9% (area percent of bendamustine) HP1, as
`shown in Formula II,
`
`Formula II
`
`N
`
`O
`
`HO
`
`N.
`
`C1
`
`at the time of release or where the HP1 is the amount of HP1
`
`present at time zero after reconstitution of a lyophilized phar-
`maceutical composition ofbendamustine as described herein.
`In a preferred embodiment is a pharmaceutical composition
`of bendamustine containing not more than about 0.5% (area
`percent of bendamustine) HP1, preferably not more than
`about 0.45%, more preferably not more than about 0.40%,
`more preferably not more than about 0.35%, even more pref-
`erably not more than 0.30%.
`Another embodiment of the invention is a lyophilized
`preparation of bendamustine containing not more than about
`0.1% to about 0.3% bendamustine dimer as shown in Formula
`III at release or at time zero after reconstitution
`
`4
`
`Yet another embodiment of the invention is a lyophilized
`preparation of bendamustine containing not more than about
`0.5%, preferably 0.15% to about 0.5%, bendamustine ethyl-
`ester, as shown in Formula IV at release or at time zero after
`reconstitution
`
`10
`
`C1
`
`15
`
`C1/\/N
`
`N\
`N
`
`Formula IV
`
`COOCHZCH3.
`
`20
`
`25
`
`30
`
`35
`
`40
`
`45
`
`50
`
`Yet another embodiment of the invention is a lyophilized
`preparation of bendamustine wherein the concentration of
`bendamustine ethylester (Formula IV) is no more than 0.2%,
`preferably 0.1%, greater than the concentration ofbendarnus-
`tine ethylester as found in the drug sub stance used to make the
`lyophilized preparation.
`In another embodiment of the invention is a lyophilized
`preparation of bendamustine containing not more than about
`0.5% to about 0.9% (area percent of bendamustine) HP1 at
`the time of drug product release. In a preferred embodiment is
`a lyophilized preparation of bendamustine containing not
`more than about 0.50% (area percent of bendamustine) HP1,
`preferably not more than about 0.45%, more preferably not
`more than about 0.40%, more preferably not more than about
`0.35%, even more preferably not more than 0.30%. An aspect
`of this embodiment is lyophilized preparations of bendarnus-
`tine containing not more than about 0.5% to about 0.9%,
`preferably 0.5%, (area percent of bendamustine) HP1 at the
`time of release of drug product where the lyophilized prepa-
`ration is packaged in a vial or other pharmaceutically accept-
`able container.
`
`In yet another aspect of the invention, the lyophilized
`preparations of bendamustine are stable with respect to the
`amount of HP1 for at least about 6 months, preferably 12
`months, preferably 24 months, to about 36 months or greater
`when stored at about 2° to about 30°. Preferred temperatures
`for storage are about 5° C. and about room temperature.
`Another embodiment of the invention is a pharmaceutical
`dosage form that includes a pharmaceutical composition of
`bendamustine containing not more than about 0.5% to about
`0.9% HP1, preferably not more than about 0.50%, preferably
`not more than about 0.45%, more preferably not more than
`about 0.40%, more preferably not more than about 0.35%,
`even more preferably not more than 0.30%, where the HP1 is
`
`HO
`
`Formula III
`
`HO
`
`H0
`
`N\
`
`\
`
`FRESENIUS KABI 1001-0011
`
`
`
`US 8,791,270 B2
`
`5
`the amount of HP1 present at release or at time zero after
`reconstitution of a lyophilized preparation of bendamustine
`ofthe present invention. In preferred aspects ofthe invention,
`the dosage form can be about 5 to about 500 mg of benda-
`mustine, about 10 to about 300 mg ofbendamustine, about 25
`mg of bendamustine, about 100 mg of bendamustine, and
`about 200 mg of bendamustine.
`Yet another embodiment of the invention is a pharmaceu-
`tical dosage form that includes a lyophilized preparation of
`bendamustine containing not more than about 0.5% to about
`0.9%, preferably 0.5%, HP1. Preferred dosage forms can be
`about 5 to about 500 mg of bendamustine, about 10 to about
`300 mg of bendamustine, about 25 mg of bendamustine,
`about 100 mg of bendamustine, and about 200 mg of benda-
`mustine.
`
`In still another embodiment, the invention includes a phar-
`maceutical composition of bendamustine including benda-
`mustine containing not more than about 0.5% to about 0.9%
`(area percent of bendamustine), preferably not more than
`about 0.50%, preferably not more than about 0.45%, more
`preferably not more than about 0.40%, more preferably not
`more than about 0.35%, even more preferably not more than
`0.30%, and a trace amount of one or more organic solvents,
`wherein said HP1 is the amount of HP1 present at release or
`time zero after reconstitution of a lyophilized pharmaceutical
`composition ofbendamustine as disclosed herein. In different
`aspects of this embodiment, the organic solvent is selected
`from one or more of tertiary butanol, n-propanol, n-butanol,
`isopropanol, ethanol, methanol, acetone, ethyl acetate, dim-
`ethyl carbonate, acetonitrile, dichloromethane, methyl ethyl
`ketone, methyl isobutyl ketone, 1-pentanol, methyl acetate,
`carbon tetrachloride, dimethyl sulfoxide, hexafluoroacetone,
`chlorobutanol, dimethyl sulfone, acetic acid, and cyclohex-
`ane. Preferred organic solvents include one or more of etha-
`nol, methanol, propanol, butanol, isopropanol, and tertiary
`butanol. A more preferred organic solvent is tertiary butanol,
`also known as TBA, t-butanol, tert-butyl alcohol or tertiary
`butyl alcohol.
`The present invention involves a method for obtaining
`agency approval for a bendamustine product, the improve-
`ment which includes setting a release specification for ben-
`damustine degradants at less than about 4.0%, preferably
`about 2.0% to about 4.0%, (area percent bendamustine) or
`otherwise to achieve the pharmaceutical compositions
`described herein. An aspe